[(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide

Base Information

Chemical Name:[(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide
CAS No.:948859-33-4
Molecular Formula:C₂F₆NO₄S₂*C₂₉H₄₁N₂Pd
Molecular Weight:804.227
Hs Code.:

Synonyms:[(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide

Suppliers and Price of [(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide

Supply Marketing:

Business phase:: The product has achieved commercial mass production^*data from LookChem market partment

Manufacturers and distributors:

Manufacture/Brand
Chemicals and raw materials
Packaging
price

Total 0 raw suppliers

Chemical Property of [(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide

Chemical Property:

Purity/Quality:

Safty Information:

Pictogram(s):
Hazard Codes:

MSDS Files:

Useful:

Technology Process of [(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide

There total 1 articles about [(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 98.0%

: bis(η3-allyl-μ-chloropalladium(II))

: 134750-23-5
N,N'-bis(2,6-diisopropylphenyl)-1,4-diaza-1,3-butadiene

: 189114-61-2
silver(I) triflimide

: 948859-33-4
[(glyoxal-bis(2,6-diisopropylphenyl)imine)allylpalladium(II)] bis(triflate)amide

Guidance literature:: In dichloromethane; byproducts: AgCl; Ar, stoich., to a soln. of N compd. added Pd compd., stirred for 5 min, Ag salt added; filtered, solvent evapd.;
DOI:10.1002/ejic.200600592